Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative drugs at affordable prices
No takes yet. Share an insight, caveat, or question.
Angelis et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: